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Purpose: Compare overall survival (OS) and breast cancer-specific survival (BCSS) outcomes of breast conser
vative therapy (BCT) and mastectomy in a large cohort of patients with early-stage triple negative breast cancer
(TNBC), using a propensity score-based matching approach.
Methods: Surveillance, Epidemiology, and End Results (SEER) database was used to study the role of RT in early
stage TNBC. Primary end points were OS and BCSS. Cox proportional hazard regression models and Kaplan-Meier
plots were used to generate the desired outcomes. Propensity score matching was done to minimize bias.
Results: 12,761 patients with T1-2N0M0 TNBC as their first malignancy were retrieved. Of these 7237 had
lumpectomy with RT, and 5524 had mastectomy only. Age, race, marital status, tumor laterality, grade and
stage, and receipt of chemotherapy were prognostic variables for OS and BCSS. Among 4848 matched subjects,
the 5-year OS was significantly higher in patients with lumpectomy and RT (89%) compared to mastectomy
alone (84.5%) (p-value <0.001). Similarly, BCSS was significantly higher in patients with lumpectomy and RT
(93%) compared to mastectomy alone (91%) (p-value <0.001). On subgroup analysis, patients who are younger
than 40 had similar survival outcomes after either mastectomy alone or lumpectomy with RT. However, those
who are older than 60, have any grade or T stage had better survival outcomes with lumpectomy and RT.
Conclusions: Overall, lumpectomy followed by RT is associated with better OS and BCSS compared to mastectomy
in T1-2N0M0 TNBC patients. Further research is needed to determine the optimal treatment strategy for specific
patient subgroups.

1. Introduction

of lumpectomy with radiotherapy, also known as breast conservative
therapy (BCT), to mastectomy in early stage breast cancer. These trials
did not account for specific breast cancer subtypes such as triple nega
tive. To date, there is no consensus on the optimal approach for treat
ment of early stage TNBC. Some studies have showcased the equivalence
of BCT to mastectomy [8], while others showed superiority of BCT in
early-stage TNBC [9]. Such studies are limited and lack certain treat
ment related variables such as type and sequence of chemotherapy.
The current study utilizes a recent cohort from the SEER database on
TNBC. Using a propensity-matched analysis., we evaluate survival (BCSS
and OS) of early stage TNBC based on treatment modality.

Breast cancer is the most common malignant tumor in women
worldwide, with around 2 million novel cases annually [1]. While
high-income countries have seen a decline in mortality rates through
changes in both clinical presentation and management [2], improve
ments can still be made to ensure better outcomes for patients.
Triple-negative breast cancer (TNBC) tumors are particularly aggressive,
occur at a younger age and have worse disease-free and overall survival
as they tend to recur and metastasize earlier [3].
Historically, clinical trials [4–7] have demonstrated the equivalence
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reported P values were 2 sided, and differences were considered statis
tically significant at P < 0.05.

2. Methods
2.1. Patient population

3. Results

SEER*Stat statistical software version 8.3.61 was used to conduct a
case-listing session. Starting in 2010, SEER database began to include
data on HER-2 receptor status. Accordingly, all cases of early stage TN
breast cancer diagnosed between 2010 and 2015 were retrieved from
the SEER research database. All selected patients were (clinical or
pathologic) T1-2N0M0 based on the 7th edition of the American Joint
Committee on Cancer. Among the selected cases, those with unknown
stage, unknown laterality, no or unknown type of surgery, unknown
tumor grade, unknown race, unknown insurance status, unknown
marital status, radiation other than adjuvant, mastectomy followed by
radiotherapy, lumpectomy without radiotherapy, duplicates, and pre
vious malignancies were excluded. No IRB approval was required as this
study did not involve patient interaction, informed consents, or patient
identification.
For each case, information on age at diagnosis, race, insurance sta
tus, marital status, tumor laterality, tumor size, tumor grade, tumor
histology, TNM stage, type of surgery, use of radiotherapy, use of
chemotherapy, and cause of death were collected. Primary end points
were overall survival (OS) and breast cancer specific survival (BCSS). OS
was measured from the date of diagnosis to the date of death from any
cause or last follow-up. BCSS was measured from the date of diagnosis to
the date of death due to breast cancer or last follow-up.
Cases were categorized into 2 groups: lumpectomy with RT, and
mastectomy alone. The groups were compared for a range of de
mographic, pathologic, and treatment variables.

3.1. Study population
We retrieved 12,761 T1-2N0M0 TNBC patients diagnosed between
2010 and 2015 who met our inclusion criteria. Of those, 7237 (57%) had
lumpectomy followed by RT, and 5524 (43%) had mastectomy alone.
Table 1 demonstrates the patients’ demographics and tumor character
istics. Except for marital status, laterality and tumor grade, all variables
were significantly different between the 2 treatment groups. Lumpec
tomy with RT patients were older (mean age 60) compared to mastec
tomy patients (mean age 57). On the other hand, the mastectomy group
had a higher proportion of tumor size >2 cm (49%) compared to the
lumpectomy with RT (34%) group. Among the 2 groups, most patients
were white (74%), insured (99%), married (60%), received chemo
therapy (71%), and had ductal (90%) and poorly differentiated grade 3
(78%) carcinoma.
Using propensity score matching, 4848 pairs of patients in the
lumpectomy with RT and mastectomy groups were matched on age,
marital status, insurance, race, T stage, laterality, tumor grade, histology
and receipt of chemotherapy using an SMD<0.1 as illustrated in Sup
plements 1 and Table 2.
3.2. Outcomes
On univariate cox proportional hazard regression, several variables
proved to have a significant prognostic effect on the OS and BCSS in the
whole cohort of TNBC patients. Asian or Pacific Islander race, being
married, right-sided tumor, lower grade disease, and receipt of chemo
therapy were significantly associated with better OS and BCSS. Younger
age and smaller tumor size had a significant protective effect in terms of
OS only. Using a multivariate cox proportional hazard regression model,
Asian or Pacific Islander race, being married, right sided tumor, lower
grade disease, and the receipt of chemotherapy retained significance as
prognostic variables associated with better BCSS. These variables in
addition to younger age and smaller tumor size also retained signifi
cance as prognostic variables associated with better OS (Table 3).
Among the propensity-matched cohort, the hazards ratio (HR) for
death associated with mastectomy alone vs. lumpectomy with RT was
1.5 (95% CI: 1.33–1.73; P value < 0.001) for OS and 1.4 (95% CI:
1.18–1.66; P value < 0.001) for BCSS (Table 4). Furthermore, lumpec
tomy with RT group had better OS and BCSS as illustrated in the KaplanMeier plots in Figs. 1 and 2 respectively. The 5-year OS was significantly
higher in patients with lumpectomy and RT (89%) compared to mas
tectomy alone (84.5%) (p-value <0.001). Similarly, BCSS was signifi
cantly higher in patients with lumpectomy and RT (93%) compared to
mastectomy alone (91%) (p-value <0.001). To eliminate the uncertainty
of the receipt of chemotherapy (patients with no/unknown status),
survival analysis was repeated only on patients who received chemo
therapy (lumpectomy + RT n = 3327; mastectomy n = 3415). Despite
the receipt of chemotherapy, lumpectomy with RT had significantly
higher 5-year OS (91.2% vs 89%, p = 0.007) and BCSS (93.3% vs 91.5%,
p = 0.021) compared to mastectomy as illustrated in the Kaplan-Meier
plots in Figs. 3 and 4, and the hazards ratios in Table 4.
Subgroup analysis was done for multiple variables (Table 5). BCSS
and OS were similar in the 2 groups for patients less than 40 years old or
aged 40–60 years. However, lumpectomy with RT had better survival
outcomes in those aged >60. Lumpectomy with RT had better BCSS
compared to mastectomy in grade 1, 2 and 3 disease in terms of OS and
in grades 3 in terms of BCSS. Regardless of race, tumor size and the
recipient of chemotherapy, lumpectomy with RT was associated with
better outcomes.

2.2. Matching
Lumpectomy with RT patients were matched to the mastectomy
alone patients on the propensity for having lumpectomy + RT. The
calipers used were ±0.25*std of logit propensity scores. For each case, a
control subject was randomly selected from the potential pool of con
trols defined by the calipers. The propensity for lumpectomy with RT
was estimated using a logistic regression model with the response var
iable being lumpectomy with RT (Y/N), and the independent variables
being age, marital status, insurance, race, T stage, laterality, grade,
histology and receipt of chemotherapy. Patients who were missing at
least one of these variables were excluded from the matching process.
Standardized mean difference (SMD) was calculated to reflect the size of
the difference between the two groups in each variable. SMD<0.1 was
considered a small difference.
2.3. Statistical analysis
Statistical analysis was performed using SPSS 25.0 software.
Continuous data were reported as means and standard deviations or
medians and ranges while categorical data were reported as counts and
percentages. Comparisons between different demographic and tumor
characteristics between the 2 groups were done using the chi-square
test, independent t-test, and nonparametric independent samples me
dian test, as appropriate. OS and BCSS for the matched cohort were
estimated by Kaplan-Meier survival curves, and survival differences
were assessed by the log-rank test. The Cox proportional hazards
regression model was conducted on univariable and multivariable an
alyses of OS and BCSS in the whole cohort.
Univariate Cox regression analysis was performed for each prog
nostic variable. Multivariate Cox regression analysis (stepwise backward
likelihood ratio) adjusting for other prognostic factors including age,
race, marital status, laterality, tumor grade, tumor size (T-stage), and
chemotherapy was performed to evaluate the effect of variables and
treatment on OS and BCSS. Hazard ratio (HR) with 95% confidence
interval (CI) for each variable and treatment group was calculated. All
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Table 1
Baseline characteristics of all patients with triple negative T1-2N0M0, according to treatment group.
Variable

Number (%)

Patients
Age at Diagnosis (years)

Race

Marital Status
Insurance Status
Laterality
Histology

Tumor Grade
T Stage/Tumor size (mm)

Chemotherapy Received
a

Mean (SD)
Median (Range)
<40
40–60
>60
White
Black
Asian or Pacific Islander
American Indian/Alaska Native
Married
Unmarried
Insured
Uninsured
Right
Left
Ductal Carcinoma
Lobular Carcinoma
Adenocarcinoma
Other
I - Well Differentiated
II - Moderately Differentiated
III - Poorly Differentiated
T1mic (microscopic foci)
T1a (≤5 mm)
T1b (>5 mm–10 mm)
T1c (>10 mm–20 mm)
T2 (>20 mm–50 mm)
Yes
No/Unknown

Total

Lumpectomy + RT

Mastectomy Alone

12,761

7237

5524

58.74 (13.18)
59 (22–99)
959 (7.5)
6059 (47.5)
5743 (45.0)
9481 (74.3)
2283 (17.9)
931 (7.3)
66 (0.5)
7657 (60.0)
5104 (40.0)
1257 (98.6)
185 (1.4)
6226 (48.8)
6535 (51.2)
11,446 (89.7)
119 (0.9)
234 (1.8)
962 (7.5)
372 (2.9)
2502 (19.6)
9887 (77.5)
142 (1.1)
804 (6.3)
1933 (15.1)
4730 (37.1)
5152 (40.4)
9060 (71.0)
3701 (29.0)

60.02 (12.10)
60 (22–99)
326 (4.5)
3377 (46.7)
3534 (4.8)
5312 (73.4)
1457 (20.1)
434 (6.0)
34 (0.5)
4343 (60.0)
2894 (40.0)
7130 (98.5)
107 (1.5)
3505 (48.4)
3732 (51.6)
6545 (90.4)
58 (0.8)
134 (1.9)
500 (6.9)
235 (3.2)
1436 (19.8)
5566 (76.9)
76 (1.1)
486 (6.7)
1319 (18.2)
2896 (40.0)
2460 (34.0)
5324 (73.6)
1913 (36.4)

57.06 (14.51)
56 (22–98)
633 (11.5)
2682 (48.6)
2209 (40.0)
4169 (75.5)
826 (15.0)
497 (9.0)
32 (0.6)
3314 (60.0)
2210 (40.0)
5446 (98.6)
78 (1.4)
2721 (49.3)
2803 (50.7)
4901 (88.7)
61 (1.1)
100 (1.8)
462 (8.4)
137 (2.5)
1066 (19.3)
4321 (78.2)
66 (1.2)
318 (5.8)
614 (11.1)
1834 (33.2)
2692 (48.7)
3736 (67.6)
1788 (32.4)

p value

SMDa

<0.001
<0.001
<0.001

0.221

<0.001

0.168

0.98

<0.001

0.76

0.057

0.36

0.017

0.005

0.064

0.02

0.054

<0.001

0.322

<0.001

0.131

Standardized Mean Difference.

Table 2
Baseline characteristics of propensity matched patients with triple negative T1-2N0M0, according to treatment group.
Value
Patients
Age at Diagnosis (years)

Race

Marital Status
Insurance Status
Laterality
Histology

Tumor Grade
T Stage/Tumor size (mm)

Chemotherapy Received
a

SMDa

Number (%)

Mean (SD)
Median (Range)
<40
40–60
>60
White
Black
Asian or Pacific Islander
American Indian/Alaska Native
Married
Unmarried
Insured
Uninsured
Right
Left
Ductal Carcinoma
Lobular Carcinoma
Adenocarcinoma
Other
I - Well Differentiated
II - Moderately Differentiated
III - Poorly Differentiated
T1mic (microscopic foci)
T1a (≤5 mm)
T1b (>5 mm–10 mm)
T1c (>10 mm–20 mm)
T2 (>20 mm–50 mm)
Yes
No/Unknown

Total

Lumpectomy + RT

Mastectomy Alone

9696 (100)

4848 (50)

4848 (50)

58 (14)
58 (22–99)
762 (7.9)
4806 (49.6)
4128 (42.6)
7253 (74.8)
1636 (16.9)
753 (7.8)
54 (0.6)
5855 (60.4)
3841 (39.6)
9551 (98.5)
145 (1.5)
4947 (51.0)
4749 (49.0)
8632 (89.0)
96 (1.0)
180 (1.9)
788 (8.1)
288 (3.0)
1918 (19.8)
7490 (77.2)
125 (1.3)
637 (6.6)
1362 (14.0)
3456 (35.6)
4116 (42.5)
6742 (69.5)
2954 (30.5)

58 (13)
58 (22–99)
320 (6.6)
2481 (51.2)
2047 (42.2)
3608 (74.4)
830 (17.1)
385 (7.9)
25 (0.5)
2957 (61.0)
1891 (39.0)
4771 (98.4)
77 (1.6)
2354 (48.6)
2494 (51.4)
4290 (88.5)
50 (1.0)
94 (1.9)
414 (8.5)
159 (3.3)
958 (19.8)
3731 (77.0)
65 (1.3)
333 (6.9)
756 (15.6)
1692 (34.9)
2002 (41.3)
3327 (68.6)
1524 (31.4)

58 (14)
58 (22–98)
442 (9.1)
2325 (48.0)
2081 (42.9)
3645 (75.2)
806 (16.6)
368 (7.6)
29 (0.6)
2898 (59.8)
1950 (40.2)
4780 (98.6)
68 (1.4)
2395 (49.4)
2453 (50.6)
4342 (89.6)
46 (0.9)
86 (1.8)
374 (7.7)
129 (2.7)
960 (19.8)
3759 (77.5)
60 (1.2)
304 (6.3)
606 (12.5)
1764 (36.4)
2114 (43.6)
3415 (70.4)
1433 (29.6)

Standardized Mean Difference.
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0.025
0.043
0.017
0.034

0.038
0.097

0.039

O. Saifi et al.

The Breast 62 (2022) 144–151

Table 3
Univariable and multivariable cox proportional hazard regression model of OS and BCSS in the whole cohort.
Univariable Cox Proportional Hazard Regression Model of OS and BCSS
Variable

OS

BCSS

HR (95% CI)
Age
Race

Marital Status
Insurance Status
Laterality
Histology

Tumor Grade
T Stage/Tumor size (mm)

Chemotherapy Received

<40
40–60
>60
White
Black
Asian or Pacific Islander
American Indian/Alaska Native
Married
Unmarried
Insured
Uninsured
Right
Left
Ductal Carcinoma
Lobular Carcinoma
Adenocarcinoma
Other
I - Well Differentiated
II - Moderately Differentiated
III - Poorly Differentiated
Tmic (microscopic foci)
T1a (≤5 mm)
T1b (>5 mm–10 mm)
T1c (>10 mm–20 mm)
T2 (>20 mm–50 mm)
No
Yes

Multivariate Cox Proportional Hazard Regression Model of OS and BCSS
Variable
Age
Race

Marital Status
Laterality
Tumor Grade
T Stage/Tumor size (mm)

Chemotherapy Received

<40
40–60
>60
White
Black
Asian or Pacific Islander
American Indian/Alaska Native
Married
Unmarried
Right
Left
I - Well Differentiated
II - Moderately Differentiated
III - Poorly Differentiated
Tmic (microscopic foci)
T1a (≤5 mm)
T1b (>5 mm–10 mm)
T1c (>10 mm–20 mm)
T2 (>20 mm–50 mm)
No/Unknown
Yes

Reference
1.0 (0.73–1.30)
2.3 (1.77–3.08)
Reference
1.0 (0.87–1.18)
0.61 (0.46–0.81)
1.1 (0.48–2.39)
Reference
1.65 (1.45–1.85)
Reference
1.1 (0.69–1.75)
Reference
1.14 (1.02–1.28)
Reference
1.1 (0.64–1.92)
1.0 (0.66–1.56)
1.2 (0.96–1.44)
Reference
1.4 (0.87–2.24)
1.8 (1.06–2.64)
Reference
2.0 (0.62–6.61)
2.4 (0.76–7.56)
4.1 (1.33–12.85)
6.5 (2.010–20.26)
Reference
0.4 (0.38–0.48)
OS
HR (95% CI)
Reference
1.1 (0.79–1.41)
2.1 (1.61–2.83)
Reference
1.0 (0.89–1.21)
0.64 (0.48–0.84)
0.86 (0.48–2.40)
Reference
1.3 (1.15–1.46)
Reference
1.1 (1.01–1.28)
Reference
1.6 (1.005–2.60)
2.5 (1.57–3.93)
Reference
2.2 (0.67–7.14)
3.1 (0.99–9.87)
6.7 (2.15–20.93)
11.9 (3.82–37.17)
Reference
0.4 (0.35–0.45)

4. Discussion

p value

HR (95% CI)

<0.001

Reference
0.87 (0.64–1.19)
1.3 (0.92–1.70)
Reference
1.1 (0.89–1.32)
0.6 (0.41–0.86)
0.92 (0.30–2.86)
Reference
1.408 (1.236–1.603)
Reference
1.4 (0.79–2.38)
Reference
1.2 (1.01–1.37)
Reference
0.72 (0.30–1.74)
0.3 (0.12–0.88)
1.1 (0.85–1.45)
Reference
1.8 (0.83–3.92)
2.7 (1.28–5.71)
Reference
793.9 (0.0–2.1E+20)
1393.2 (0.0–3.7E+20)
2799.7 (0.0–7.3E+20)
5233.4 (0.0–1.4E+21)
Reference
0.8 (0.68–0.94)

p value

BCSS
HR (95% CI)

0.86
<0.001
0.84
0.001
0.87
<0.001
0.69
0.027
0.7
0.95
0.13
0.17
0.027
0.24
0.14
0.01
0.001

0.71
<0.001
0.64
0.002
0.86
<0.001
0.03
0.048
0.002
0.2
0.052
0.001
<0.001
<0.001

Reference
1.0 (0.84–1.25)
0.6 (0.42–0.89)
0.9 (0.30–2.87)
Reference
1.3 (1.07–1.46)
Reference
1.2 (1.02–1.38)
Reference
1.9 (0.87–4.10)
3.0 (1.44–6.47)

Reference
0.7 (0.62–0.86)

p value
0.39
0.15
0.41
0.006
0.89
<0.001
0.26
0.036
0.47
0.026
0.45
0.13
0.009
0.74
0.72
0.7
0.68
0.006

p value

0.8
0.01
0.89
0.005
0.029
0.11
0.004

<0.001

Kindts et al. studied 439 non metastatic TNBC patients and reported
better BCSS for those who underwent BCT as compared to mastectomy
[19]. More recently a large, non-propensity matched SEER analysis on
early stage TNBC showed BCT to be associated with better OS and BCSS
compared to mastectomy [20]. Such discrepancies can be attributed to
differences in the study populations, the limited power of the statistical
comparisons, the effect of confounders and selection bias.
To better address the above question, we used the SEER database and
performed propensity score matching in order to minimize selection
bias. As shown in Figs. 1 and 2, BCT was superior to mastectomy alone in
terms of OS (log rank p < 0.001) and BCSS (log rank p < 0.001). This
concurs with the above mentioned non-propensity matched SEER
analysis study [20] and with a recent report whereby patients with T1N0
disease treated with BCT had better 10-year OS and distant
metastasis-free survival compared to those who had mastectomy [21].

Previous historical landmark studies and clinical trials showed that
radiation added to lumpectomy is equivalent to mastectomy in early
stage breast cancer patients [4–7]. Similarly, the largest observational
study to date recently revealed the comparable efficacy of BCT to mas
tectomy [10]. However, recent observational studies suggested that BCT
is superior to mastectomy in early stage breast cancer [11–15]. There
fore, it is essential to reconsider the comparison between BCT and
mastectomy in the modern era.
Few studies reported mixed results when comparing BCT to mas
tectomy in early stage TNBC. Abdulkarim et al. reported better locore
gional control in the BCT group, but similar OS outcomes (n = 468) [16].
Similarly, others [17,18] reported comparable OS between the BCT and
total mastectomy groups in early stage TNBC patients. In contrast,
147
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Similarly, others showed superiority of BCT for early stage breast cancer
regardless of subtype [11–15].
We stratified the matched cohort based on select clinical variables to
account for possible cofounding effects. For patients younger than 40
years old or aged 40–60 years, the treatment modality did not affect the
cancer specific and overall survival. This is supported by the results of
some observational studies that showed no significant difference be
tween BCT and mastectomy in early stage breast cancer patients aged
less than 40 years [22,23]. In terms of BCSS and tumor grade, lumpec
tomy with RT had protective effect for grade 3 disease only. This might
indicate that treatment modality does not make a difference for low
grade tumors (1–2). As shown in Table 5, other subcategories, demon
strated better survival outcome with BCT vs. mastectomy.
There are multiple potential explanations for the additional benefit
RT adds to lumpectomy when compared to mastectomy. RT might help
eliminate microscopic disease and possible microscopic LN involvement
that are not targeted by mastectomy alone reducing locoregional

Table 4
OS and BCSS hazard ratios associated with radiation and extent of surgery in the
matched cohort.
Comparison

OS for all patients

OS for patients who received
chemotherapy

Hazard Ratio
(95% CI)

P Value

Hazard Ratio
(95% CI)

P
Value

Lumpectomy +
RT
Mastectomy

1 [Reference]

<0.001

1 [Reference]

0.007

1.5 (1.33–1.73)

1.3 (1.07–1.55)

Comparison

BCSS for all patients

Lumpectomy +
RT
Mastectomy

Hazard Ratio
(95% CI)

P
Value

BCSS for patients who
received chemotherapy
Hazard Ratio
P
(95% CI)
Value

1 [Reference]

<0.001

1 [Reference]

1.4 (1.18–1.66)

0.022

1.3 (1.04–1.58)

Fig. 1. Kaplan-Meier plot of overall survival (OS) by treatment group in the matched cohort.

Fig. 2. Kaplan-Meier plot of breast cancer specific survival (BCSS) by treatment group in the matched cohort.
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Fig. 3. Kaplan-Meier Plot of Overall Survival (OS) by Treatment Group in the Matched Cohort for Patients who Received Chemotherapy.

Fig. 4. Kaplan-Meier Plot of Breast Cancer Specific Survival (BCSS) by Treatment Group in the Matched Cohort for Patients who Received Chemotherapy.

recurrence (LRR). Onitilo et al. reported better LRR and OS for patients
receiving lumpectomy followed by RT compared to mastectomy [24].
Furthermore, TNBC patients are more likely to have BRCA mutations
[25], rendering the tumor unable to repair the DNA damage. This can
lead to increased radio-sensitivity [26] which might explain the better
outcomes associated with RT in our study. Unfortunately, we were un
able to obtain data on BRCA status through SEER, which limits our
ability to confirm this hypothesis. Finally, mastectomy is known to be
more morbid than BCT, although efforts have been spent to decrease its
morbidity by changing the surgery technique [27]. However, one should
note that despite minimizing the effect of confounding with propensity
score matching, some confounders are not available and cannot be easily
adjusted for. For example, SEER does not record mode of presentation
(screening or symptomatic) as screen-detected disease have a better
prognosis than its symptomatic counterpart. Screen-detected patients
are more likely to be treated by BCT and thus have improved survival
outcomes. The observation that the apparent improvements in survival
after BCT in our study were evident in older patients but not in younger

patients (who are less likely to be detected through screening) is in
keeping with this possibility.
As for the prognostic factors, Asian and non-pacific race had better
survival. This concurs with previously reported results that showed
lower breast cancer actuarial risk of death among Asian women [28].
Being married conferred a survival effect as well. This can be attributed
to the parity, breastfeeding and social support effect which is proven to
decrease the risk of breast cancer [29] even in TNBC [30]. Lower grade
disease and smaller tumor size also provided survival benefit in these
patients. Furthermore, the receipt of chemotherapy contributed to better
survival in these patients. Chemotherapy currently serves as the back
bone of systemic therapy in TNBC as such tumors lack sensitivity to ER
and HER-2 blockade targeting agents [31]. It is worth mentioning that
BCT was also associated with better OS and BCSS compared to mastec
tomy in patients who received chemotherapy indicating the added
benefit radiation can provide despite the receipt of systemic therapies.
Although it stands as one of the largest studies on the topic, the
current analysis has several limitations that are worth discussing. First,
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Table 5
Hazard Ratios for BCSS and OS Associated with Lumpectomy and Radiotherapy vs Mastectomy Alone for Various Propensity-Matched Patient Subgroups.
Subgroup
Age at Diagnosis (years)

<40
40–60
>60

Race

White
Black

Tumor Grade

I - Well Differentiated
II - Moderately Differentiated
III - Poorly Differentiated

T Stage/Tumor Size

T1mic + T1a (≤5 mm)
T1b (>5 mm–10 mm)
T1c (>10 mm–20 mm)
T2 (>20 mm–50 mm)

Chemotherapy Received

Yes
No/Unknown

Comparison

HR for BCSS (CI 95%)

Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy
Lumpectomy Plus Radiotherapy
Mastectomy

Reference
1.5 (0.77–2.77)
Reference
1.2 (0.95–1.63)
Reference
1.5 (1.18–1.91)
Reference
1.4 (1.14–1.68)
Reference
1.4 (0.93–2.01)
Reference
7.4 (0.90–61.57)
Reference
1.2 (0.76–1.86)
Reference
1.4 (1.16–1.69)
Reference
1.3 (1.06–1.65)
Reference
2.3 (1.13–4.66)
Reference
1.3 (0.92–1.71)
Reference
1.3 (1.06–1.65)
Reference
1.3 (1.04–1.58)
Reference
1.7 (1.25–2.25)

p value
0.25
0.11
0.001
0.001
0.11
0.06
0.44
<0.001
0.012
0.022
0.15
0.012
0.022
0.01

HR for OS (CI 95%)
Reference
1.7 (0.89–3.12)
Reference
1.1 (0.87–1.40)
Reference
1.7 (1.48–2.05)
Reference
1.5 (1.29–1.73)
Reference
1.5 (1.12–2.06)
Reference
3.5 (1.27–9.80)
Reference
1.6 (1.19–2.22)
Reference
1.5 (1.26–1.69)
Reference
1.6 (1.32–1.88)
Reference
1.6 (1.03–2.61)
Reference
1.3 (1.03–1.61)
Reference
1.6 (1.32–1.88)
Reference
1.3 (1.07–1.55)
Reference
1.8 (1.53–2.22)

p value
0.11
0.42
<0.001
<0.001
0.007
0.016
0.003
<0.001
<0.001
0.037
0.03
<0.001
0.007
<0.001
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this is a retrospective non-randomized study, where treatment might
have been given according to physician preferences and some specific
factors that are not captured by the dataset. Second, SEER database does
not have data on locoregional recurrence, which is an important
endpoint for radiotherapy. Furthermore, SEER has data on HER-2 re
ceptor status as of 2010, limiting the study cohort to 5 years only
(2010–2015). Moreover, important variables such as BRCA mutation or
the sequence of chemotherapy could not be retrieved. Other major
limitations include the inability to capture the sequence of chemo
therapy (neoadjuvant vs adjuvant) and its definite absence in the
treatment paradigm. Moreover, we did not provide further analysis on
ethnicity, rather we limited it to race only.
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5. Conclusion
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TNBC is an aggressive form of breast cancer with poor prognosis. No
representative clinical trials assessed the difference between BCT and
mastectomy in these patients. Our propensity-matched analysis study
revealed that RT when added to lumpectomy is associated with better
OS and BCSS compared to mastectomy. Further studies should be con
ducted to optimize the treatment modality according breast cancer
biology.
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